基于增强CT影像组学的NSCLC肿瘤纤维化无创分层与预后模型RaFiST
多中心回顾性研究纳入532例切除的非小细胞肺癌患者,以组织病理胶原分数量化肿瘤纤维化,利用治疗前增强CT影像组学开发RaFiST。纤维化评分为DFS和OS的独立风险因素,最佳截断值11.12%;RaFiST预测肿瘤纤维化AUC训练队列0.879、测试队列0.813,联合模型5年DFS AUC 0.827。RaFiST-High患者生存更差,并与细胞外基质重塑、缺氧及免疫抑制通路相关。
要点
- RaFiST基于治疗前增强CT影像组学,可无创预测NSCLC肿瘤纤维化并分层。
- 纤维化评分最佳截断值11.12%,RaFiST-High患者DFS与OS均显著更差(all p < 0.01)。
- 联合Clinical-RaFiST模型5年DFS AUC 0.827,优于单纯临床及直接影像组学模型,有助术后辅助治疗决策。
核心结论
- 肿瘤纤维化是非小细胞肺癌的独立预后风险因素。
- RaFiST可作为基于治疗前增强CT的影像组学生物标志物,用于肿瘤纤维化无创分层和预后预测。
研究设计与样本
- 多中心回顾性研究,纳入532例接受切除的非小细胞肺癌患者。
- 以组织病理胶原分数量化肿瘤纤维化作为参考标准。
- 利用治疗前增强CT影像组学开发RaFiST,设训练队列与外部测试队列。
- 对RaFiST高低组进行转录组学分析,探索潜在分子机制。
诊断标准与关键数值
- 组织病理胶原分数最佳截断值为11.12%,用于区分高纤维化与低纤维化组。
- RaFiST预测肿瘤纤维化的AUC:训练队列0.879,测试队列0.813。
- 多变量Cox回归显示纤维化评分为两个中心DFS和OS的独立风险因素。
- 联合Clinical-RaFiST模型5年DFS AUC为0.827,优于基线临床模型和直接影像组学模型。
- RaFiST-High患者在两个队列中生存均显著更差(all p < 0.01)。
临床应用与阅片要点
- 对NSCLC治疗前增强CT可借助RaFiST进行肿瘤纤维化无创分层。
- RaFiST-High提示术后DFS与OS较差,可辅助早期识别需及时辅助治疗的患者。
- 联合Clinical-RaFiST模型5年DFS AUC 0.827,优于单纯临床与直接影像组学模型,可结合临床风险综合判读。
局限性
- 本研究为多中心回顾性设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Tumor fibrosis plays a critical role in driving therapeutic heterogeneity and drug resistance. However, relevant research in non-small cell lung cancer (NSCLC) remains limited. This study aimed to determine the prognostic value of tumor fibrosis and develop a novel radiomics fibrosis stratification tool (RaFiST) for non-invasive patient stratification.
MATERIALS AND METHODS: In this multicenter retrospective study of 532 patients with resected NSCLC, tumor fibrosis was histopathologically quantified via collagen fraction. RaFiST was developed using pre-treatment contrast-enhanced CT scans from training and external test cohorts. Prognostic performance was subsequently compared among clinical, direct radiomics, and combined models. Transcriptomic analysis investigated the model's underlying molecular mechanisms.
RESULTS: Multivariable Cox regression revealed that the fibrosis score was an independent risk factor for disease-free survival (DFS) and overall survival (OS) at both centers. An optimal cutoff of 11.12% stratified patients into high- and low-fibrosis groups. RaFiST demonstrated excellent performance in predicting tumor fibrosis, achieving an area under the curve (AUC) of 0.879 in the training cohort and 0.813 in the test cohort. RaFiST-High patients exhibited significantly worse survival across both cohorts (all p < 0.01). Furthermore, the combined Clinical-RaFiST model outperformed the baseline clinical and direct radiomics models, yielding a 5-year DFS AUC of 0.827. Transcriptomic analysis associated the RaFiST-High group with pathways for extracellular matrix remodeling, hypoxia, and immune suppression.
CONCLUSION: Tumor fibrosis is an independent prognostic risk factor in NSCLC. RaFiST provides a robust, non-invasive imaging biomarker for tumor fibrosis stratification and prognostic prediction.
KEY POINTS: Question Tumor fibrosis plays a critical role in tumor therapeutic heterogeneity and drug resistance. However, relevant research in non-small cell lung cancer (NSCLC) remains relatively limited. Findings Tumor fibrosis is an independent prognostic factor in NSCLC, and radiomics fibrosis stratification tool (RaFiST), a CT-based radiomics model provides a robust non-invasive biomarker for fibrosis stratification and outcome prediction. Clinical relevance RaFiST offers a non-invasive, reproducible framework to evaluate tumor fibrosis in NSCLC, thereby enabling the earlier identification of postoperative patients with poor prognoses for prompt adjuvant therapy.
引用
- Zong, Wang, Li, et al. RaFiST: a radiomics model for non-invasive stratification of tumor fibrosis and prognostic prediction in non-small cell lung cancer. Eur Radiol. 2026. PMID: 42622885. doi:10.1007/s00330-026-12764-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。